157 related articles for article (PubMed ID: 25253779)
1. MEK inhibitor for gastric cancer with MEK1 gene mutations.
Sogabe S; Togashi Y; Kato H; Kogita A; Mizukami T; Sakamoto Y; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Tomida S; Yasuda T; Takeyama Y; Okuno K; Nishio K
Mol Cancer Ther; 2014 Dec; 13(12):3098-106. PubMed ID: 25253779
[TBL] [Abstract][Full Text] [Related]
2. EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.
Mizukami T; Togashi Y; Sogabe S; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Nakajima TE; Boku N; Nishio K
Int J Oncol; 2015 Aug; 47(2):499-505. PubMed ID: 26081723
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
4. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
[TBL] [Abstract][Full Text] [Related]
5. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.
Wang H; Daouti S; Li WH; Wen Y; Rizzo C; Higgins B; Packman K; Rosen N; Boylan JF; Heimbrook D; Niu H
Cancer Res; 2011 Aug; 71(16):5535-45. PubMed ID: 21705440
[TBL] [Abstract][Full Text] [Related]
6. CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
Kim DJ; Lee MH; Reddy K; Li Y; Lim DY; Xie H; Lee SY; Yeom YI; Bode AM; Dong Z
Carcinogenesis; 2013 May; 34(5):1134-43. PubMed ID: 23354306
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J; Greshock J; Holbrook JD; Gilmartin A; Zhang X; McNeil E; Conway T; Moy C; Laquerre S; Bachman K; Wooster R; Degenhardt Y
Mol Cancer Ther; 2012 Mar; 11(3):720-9. PubMed ID: 22169769
[TBL] [Abstract][Full Text] [Related]
8. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
9. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
10. SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors.
Kiga M; Nakayama A; Shikata Y; Sasazawa Y; Murakami R; Nakanishi T; Tashiro E; Imoto M
Sci Rep; 2015 Feb; 5():8155. PubMed ID: 25640451
[TBL] [Abstract][Full Text] [Related]
11. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
12. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
Gannon HS; Kaplan N; Tsherniak A; Vazquez F; Weir BA; Hahn WC; Meyerson M
Mol Cancer Res; 2016 Feb; 14(2):207-15. PubMed ID: 26582713
[TBL] [Abstract][Full Text] [Related]
13. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
14. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
Zhang J; Wang J; Guo Q; Wang Y; Zhou Y; Peng H; Cheng M; Zhao D; Li F
Cancer Lett; 2012 Apr; 317(1):24-32. PubMed ID: 22085492
[TBL] [Abstract][Full Text] [Related]
15. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
Mallon R; Feldberg L; Kim S; Collins K; Wojciechowicz D; Kohler C; Kovacs D; Discafani C; Zhang N; Wu B; Floyd B; Powell D; Berger D
Mol Cancer Ther; 2004 Jun; 3(6):755-62. PubMed ID: 15210862
[TBL] [Abstract][Full Text] [Related]
16. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Yoon YK; Kim HP; Han SW; Hur HS; Oh DY; Im SA; Bang YJ; Kim TY
Mol Cancer Ther; 2009 Sep; 8(9):2526-36. PubMed ID: 19755509
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
[TBL] [Abstract][Full Text] [Related]
18. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K).
Van Dort ME; Hong H; Wang H; Nino CA; Lombardi RL; Blanks AE; Galbán S; Ross BD
J Med Chem; 2016 Mar; 59(6):2512-22. PubMed ID: 26943489
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1/2.
Yoshida T; Kakegawa J; Yamaguchi T; Hantani Y; Okajima N; Sakai T; Watanabe Y; Nakamura M
Oncotarget; 2012 Dec; 3(12):1533-45. PubMed ID: 23237773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
